HC Wainwright & Co. Reiterates Buy on Iovance Biotherapeutics, Maintains $38 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Iovance Biotherapeutics (NASDAQ:IOVA) and maintained a $38 price target.
August 09, 2023 | 10:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a 'Buy' rating on Iovance Biotherapeutics, maintaining a $38 price target.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for the stock. The maintained price target of $38 indicates the firm's continued confidence in the company's potential. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100